Risk to Medical Gas and Machinery Sales from Drug Price Revisions
First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2023.
0 other companies' latest entry also says "Mitigated".
- FY2023MitigatedAnnual report
「As measures to address these risks, the Group monitors information released by the Ministry of Health, Labour and Welfare on drug price revisions as it becomes available. It also actively provides services that can reduce the maintenance and management costs of supply equipment to meet customer needs, while working to retain existing customers and acquire new ones.」
In addition to monitoring information on drug price revisions, the Group explicitly identifies the provision of services that reduce supply equipment maintenance and management costs as a risk response measure. - FY2022RestatedAnnual report
「Selling prices are often determined through competitive bidding, and the Group may lose business with existing customers as a result of such bidding. In addition, the Group's sales or earnings may be affected depending on the details of revisions to drug prices.」
The healthcare-related business risks, including drug price revisions, competitive-bidding price determination and the possibility of losing existing customers, continue to be disclosed. - FY2020ReframedAnnual report
「Selling prices are often determined through competitive bidding, and the Group may lose business with existing customers as a result of such bidding. In addition, the Group's sales or earnings may be affected depending on the details of revisions to drug prices.」
The healthcare-related business risk is described more specifically by adding competitive-bidding price determination and the possibility of losing existing customers to the existing risk of drug price revisions. - FY2017RestatedAnnual report
「The Group sells medical gases and medical equipment to medical institutions, and the Group's operating results and financial condition may be affected depending on the details of revisions to drug prices.」
The potential impact of revisions to drug prices on the healthcare-related business is reiterated. - FY2016First statedAnnual report
「The Group sells medical gases and medical equipment to medical institutions, and the Group's operating results and financial condition may be affected depending on the details of revisions to drug prices.」
The details of revisions to the drug pricing system are identified as a factor that may affect the operating results and financial condition of the healthcare-related business.